PURPOSE/ OBJECTIVES: To longitudinally explore changes, similarities, differences, and interrelations in the sleep-wake parameters of patient-caregiver dyads throughout adjuvant chemotherapy for breast cancer. . DESIGN: Observational, repeated-measures, dyadic study. . SETTING: Four ambulatory oncology clinics in Scotland. . SAMPLE: 48 dyads consisting of patients and their primary informal caregivers. . METHODS: Four dyadic, self-reported sleep-wake assessments took place before chemo-therapy (T0), during chemotherapy cycles 1 (T1) and 4 (T2), and after chemotherapy (T3). Dyads completed the Pittsburgh Sleep Quality Index. Multilevel hierarchical linear modeling was used to explore dyadic data. . MAIN RESEARCH VARIABLES: Perceived sleep quality, sleep onset latency (SOL), total sleep time, habitual sleep efficiency, wake after sleep onset, daily disturbance, daytime napping duration, overall sleep-wake impairment. . FINDINGS: The majority of dyads had at least one poor sleeper throughout the study; 25%-35% were dyads of concurrent poor sleepers. Curvilinear patterns of change were evident for patients' (but not caregivers') sleep-wake parameters, steadily deteriorating from pre- to midtreatment, then leveling off close to baseline. Average trajectories were significantly different between the dyad members but indicative of a trend for concurrent deterioration at T2. Dyad members' perceived sleep quality, SOL, and overall sleep-wake impairment were closely interrelated; wake variables remained uncoupled. . CONCLUSIONS: Despite overall differences in magnitude, sleep problems may be concurrently present in both dyad members, covary, and peak midway through chemotherapy. . IMPLICATIONS FOR NURSING: Dyadic sleep assessments can shed light on potential areas of sleep interaction to enable interventions to support care dyads at risk of sleep distress during chemotherapy for breast cancer.
PURPOSE/ OBJECTIVES: To longitudinally explore changes, similarities, differences, and interrelations in the sleep-wake parameters of patient-caregiver dyads throughout adjuvant chemotherapy for breast cancer. . DESIGN: Observational, repeated-measures, dyadic study. . SETTING: Four ambulatory oncology clinics in Scotland. . SAMPLE: 48 dyads consisting of patients and their primary informal caregivers. . METHODS: Four dyadic, self-reported sleep-wake assessments took place before chemo-therapy (T0), during chemotherapy cycles 1 (T1) and 4 (T2), and after chemotherapy (T3). Dyads completed the Pittsburgh Sleep Quality Index. Multilevel hierarchical linear modeling was used to explore dyadic data. . MAIN RESEARCH VARIABLES: Perceived sleep quality, sleep onset latency (SOL), total sleep time, habitual sleep efficiency, wake after sleep onset, daily disturbance, daytime napping duration, overall sleep-wake impairment. . FINDINGS: The majority of dyads had at least one poor sleeper throughout the study; 25%-35% were dyads of concurrent poor sleepers. Curvilinear patterns of change were evident for patients' (but not caregivers') sleep-wake parameters, steadily deteriorating from pre- to midtreatment, then leveling off close to baseline. Average trajectories were significantly different between the dyad members but indicative of a trend for concurrent deterioration at T2. Dyad members' perceived sleep quality, SOL, and overall sleep-wake impairment were closely interrelated; wake variables remained uncoupled. . CONCLUSIONS: Despite overall differences in magnitude, sleep problems may be concurrently present in both dyad members, covary, and peak midway through chemotherapy. . IMPLICATIONS FOR NURSING: Dyadic sleep assessments can shed light on potential areas of sleep interaction to enable interventions to support care dyads at risk of sleep distress during chemotherapy for breast cancer.
Authors: Kelly M Shaffer; Allison J Applebaum; Katherine N DuHamel; Sheila N Garland; Philip Gehrman; Jun J Mao Journal: Behav Sleep Med Date: 2018-11-26 Impact factor: 2.964
Authors: Amy K Otto; Brian D Gonzalez; Richard E Heyman; Susan T Vadaparampil; Lee Ellington; Maija Reblin Journal: Psychooncology Date: 2019-11-12 Impact factor: 3.894
Authors: Amanda N Gesselman; Silvia M Bigatti; Justin R Garcia; Kathryn Coe; David Cella; Victoria L Champion Journal: Psychooncology Date: 2016-07-04 Impact factor: 3.894
Authors: Pinky Shani; Kristin Raeesi; Eli Walter; Kai Lewis; Wanyi Wang; Lorenzo Cohen; Gloria Y Yeh; Cecile A Lengacher; Peter M Wayne Journal: Pilot Feasibility Stud Date: 2021-03-19